However, when considered as a separate category, all 18 samples with mutations in both PIK3CA and PTEN genes (breast cancer, endometrial carcinoma, ovarian cancer and urinary bladder cancer) also displayed mTOR-pathway activation (χ2p=0.0471; Table 2). This evidence concerns the gene PIK3CA and ovarian cancer.